富马酸丙酚替诺福韦与恩替卡韦治疗乙型肝炎病毒相关慢加急性肝衰竭的效果对比

彭文婷; 顾慧敏; 蒋川; 刘槿晴; 张暕; 傅蕾

doi:10.11817/j.issn.1672-7347.2022.210578

您当前的位置：

首页 >

文章列表页 >

富马酸丙酚替诺福韦与恩替卡韦治疗乙型肝炎病毒相关慢加急性肝衰竭的效果对比

扫描看全文

文章被引用时，请邮件提醒。

提交

论著 | 更新时间：2022-11-11

富马酸丙酚替诺福韦与恩替卡韦治疗乙型肝炎病毒相关慢加急性肝衰竭的效果对比
Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure
中南大学学报(医学版) 中南大学学报(医学版) 2022年47卷第2期页码：194-201
作者机构：

1.中南大学湘雅医院感染病科，长沙 410078
作者简介：

彭文婷，Email: pengwenting_123@163.com, ORCID: 0000-0002-9072-1332
傅蕾，Email: fulei92@126.com, ORCID: 0000-0001-7550-1254
基金信息：

国家自然科学基金(81770623;81974080;82170640);湖南省科技厅重点领域研发计划(2020SK30272);王宝恩肝纤维化研究基金(2021039)
DOI：10.11817/j.issn.1672-7347.2022.210578
中图分类号：
CSTR：

彭文婷, 顾慧敏, 蒋川, 等. 富马酸丙酚替诺福韦与恩替卡韦治疗乙型肝炎病毒相关慢加急性肝衰竭的效果对比[J]. 中南大学学报(医学版), 2022,47(2):194-201.

PENG Wenting, GU Huimin, JIANG Chuan, et al. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Central South University. Medical Science, 2022,47(2):194-201.
彭文婷, 顾慧敏, 蒋川, 等. 富马酸丙酚替诺福韦与恩替卡韦治疗乙型肝炎病毒相关慢加急性肝衰竭的效果对比[J]. 中南大学学报(医学版), 2022,47(2):194-201. DOI： 10.11817/j.issn.1672-7347.2022.210578.

PENG Wenting, GU Huimin, JIANG Chuan, et al. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Central South University. Medical Science, 2022,47(2):194-201. DOI： 10.11817/j.issn.1672-7347.2022.210578.

摘要

目的,2,乙型肝炎病毒相关慢加急性肝衰竭(hepatitis B virus-related acute-on-chronic liver failure，HBV-ACLF)是我国最常见的肝衰竭类型，病死率很高。早期快速降低HBV-DNA载量可提高HBV-ACLF患者的存活率，目前常用的药物有核苷(酸)类似物，如恩替卡韦(entecavir，ETV)、替诺福韦等。新上市的富马酸丙酚替诺福韦(tenofovir alafenamide fumarate，TAF)以其更强效的抗病毒作用、更高的转氨酶复常率、更好的骨肾安全性及零耐药等优点，得到临床医师的极大关注。但关于TAF治疗中国HBV-ACLF患者的疗效及安全性的临床研究数据较少，且缺乏药物经济学评价。本研究旨在比较TAF与ETV治疗HBV-ACLF的疗效、安全性和经济学成本。,方法,2,回顾性分析2020年5月至2021年3月于中南大学湘雅医院住院的HBV-ACLF患者196例，其中前期66例、早期57例、中期43例和晚期30例。根据用药情况分为TAF组80例，ETV组116例。比较2组患者治疗前、治疗2、4周的生化及病毒学指标；治疗12周，比较2组患者的肝移植率+病死率、并发症发生率等。采用最小成本分析法比较2种药物的成本-效果比值，进行药物经济学评价。,结果,2,治疗4周时，2组疗效(肝功能、病毒载量)差异均无统计学意义(均,P,>,0.05)；与ETV组相比，TAF组的血肌酐水平更低[(80.35±18.77) μmol/L vs (105.59±82.32) μmol/L，,P,<,0.05]，估计肾小球滤过率水平更高[(95.65±23.21) mL/(min·1.73 m,2,) vs (82.68±26.32) mL/(min·1.73 m,2,)，,P,<,0.05]。治疗12周时，2组的总体肝移植率+病死率差异无统计学意义(,P,>,0.05)，TAF组肝衰竭前期患者的肝移植率+病死率低于ETV组(0 vs 13.89%，,P,<,0.05)。在肝衰竭早期、中期、晚期，2组的肝移植率+病死率差异均无统计学意义(13.04% vs 17.65%、37.50% vs 37.04%、54.55% vs 68.42%，均,P,>,0.05)。在12周的观察期内，2组均未观察到药物相关不良事件发生。TAF组的成本-效果比值较低，治疗成本较低。,结论,2,TAF与ETV在改善HBV-ACLF患者肝功能及降低病毒载量方面无明显差异；二者的安全性相当。TAF对肾功能的保护更具优势，可降低肝衰竭前期患者的肝移植率+病死率；TAF在药物经济学评价方面优于ETV。

Abstract

Objective,2,Hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is the most common type of liver failure in China, with a high mortality. Early rapid reduction of HBV-DNA load can improve the survival rate of HBV-ACLF patients. At present, the commonly used drugs are nucleoside (acid) analogues, such as entecavir (ETV), tenofovir, and so on. The newly listed tenofovir alafenamide fumarate (TAF) has attracted great attention of clinicians because of its stronger antiviral effect, higher transaminase normalization rate, better bone and kidney safety, and zero drug resistance. However, there are few clinical research data on the efficacy and safety of TAF in the treatment of Chinese HBV-ACLF patients, and there is a lack of pharmacoeconomic evaluation. This study aims to compare the efficacy, safety, and cost-effectiveness between TAF and ETV in patients with HBV-ACLF.,Methods,2,The data were collected from 196 HBV-ACLF patients (80 patients in the TAF group and 116 patients in the ETV group) who were hospitalized in Xiangya Hospital, Central South University from May 2020 to March 2021. Biochemistry and virology were detected before and after treatment (at baseline, Week 2, 4, and 12). Clinical features, disease prognosis, and cost-effectiveness were compared between the 2 groups. According to the baseline, HBV-ACLF patients were divided into 4 stages including pre-liver failure stage, early stage, medium stage, and end stage. And the liver transplantation rate and mortality was also compared. Pharmacoeconomic evaluation was taken using cost-effectiveness analysis and cost minimization analysis．,Results,2,After 4 weeks of treatment, there were no significant differences in the efficacy (liver function, viral load) between the 2 groups (all ,P,>,0.05). The TAF group showed lower creatinine [(80.35±18.77) μmol/L vs (105.59±82.32) μmol/L,P,<,0.05] and higher estimated glomerular filtration rate (eGFR) levels [(95.65±23.21) mL/(min·1.73 m,2,) vs (82.68±26.32) mL/(min·1.73 m,2,),P,<,0.05] than the ETV group. After 12 weeks of treatment, the analysis of overall the liver transplantation rate and mortality between the 2 groups showed similar conclusion. However, the TAF group had a lower the liver transplantation rate and mortality than the ETV group in patients with pre-liver failure (0,vs,13.89%,P,<,0.05). No evident distinction was found in the liver transplantation rate and mortality during the early, medium, or end stages of liver failure (13.04% vs 17.65%, 37.50% vs 37.04%, and 54.55% vs 68.42%, respectively). Ratio of cost to effectiveness in the ETV group was higher than that in the TAF group.,Conclusion,2,TAF is not more efficient than ETV group in improving liver function and reducing viral load for HBV-ACLF patients and they also show similar safety. However, TAF has a greater advantage over ETV not only in preserving renal function, but also in reducing the liver transplantation rate and mortality in patients with pre-liver failure. TAF can provide economic benefit to patients with HBV-ACLF.

关键词

乙型肝炎病毒相关慢加急性肝衰竭富马酸丙酚替诺福韦恩替卡韦疗效安全性成本-效果分析

Keywords

hepatitis B virus-related acute-on-chronic liver failuretenofovir alafenamide fumarateentecavirefficacysafetycost-effectiveness

references

中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版)[J]. 中华临床感染病杂志, 2015, 8(6): 481-503. https://doi.org/10.3760/cma.j.issn.1674-2397.2015.06.001https://doi.org/10.3760/cma.j.issn.1674-2397.2015.06.001.

Hepatology Branch of Chinese Medical Association, Infectious Diseases Branch of Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: 2015 update[J]. Chinese Journal of Clinical Infectious Diseases, 2015, 8(6): 481-503. https://doi.org/10.3760/cma.j.issn.1674-2397.2015.06.001https://doi.org/10.3760/cma.j.issn.1674-2397.2015.06.001.

中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 中华传染病杂志, 2019, 37(1): 1-9. https://doi.org/10.3760/cma.j.issn.1000-6680.2019.01.001https://doi.org/10.3760/cma.j.issn.1000-6680.2019.01.001.

Liver Failure and Artificial Liver Group, Infectious Diseases Branch of Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Hepatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of liver failure (2018 Edition)[J]. Chinese Journal of Infectious Diseases, 2019, 37(1): 1-9. https://doi.org/10.3760/cma.j.issn.1000-6680.2019.01.001https://doi.org/10.3760/cma.j.issn.1000-6680.2019.01.001.

Wu TZ, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. https://doi.org/10.1136/gutjnl-2017-314641https://doi.org/10.1136/gutjnl-2017-314641.

Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. https://doi.org/10.1016/S2468-1253(16)30024-3https://doi.org/10.1016/S2468-1253(16)30024-3.

Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206. https://doi.org/10.1016/S2468-1253(16)30107-8https://doi.org/10.1016/S2468-1253(16)30107-8.

Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. https://doi.org/10.1053/he.2000.5852https://doi.org/10.1053/he.2000.5852.

中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. https://doi.org/10.3969/j.issn.1001-5256.2018.10.007https://doi.org/10.3969/j.issn.1001-5256.2018.10.007.

Hepatology Branch of Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2076-2089. https://doi.org/10.3969/j.issn.1001-5256.2018. 10.007https://doi.org/10.3969/j.issn.1001-5256.2018.10.007.

柳龙根, 陆建春, 薛源, 等. 恩替卡韦和拉米夫定治疗早期慢加急性肝衰竭的成本-效果分析[J]. 中国医师杂志, 2016, 18(3): 343-346. https://doi.org/10.3760/cma.j.issn.1008-1372.2016.03.006https://doi.org/10.3760/cma.j.issn.1008-1372.2016.03.006.

LIU Longgen, LU Jianchun, XUE Yuan, et al. Cost effectiveness analysis of entecavir and lamivudine in the treatment of early chronic and acute liver failure[J]. Chinese Journal of Physicians, 2016, 18(3):343-346. https://doi.org/10.3760/cma.j.issn.1008-1372.2016.03.006https://doi.org/10.3760/cma.j.issn.1008-1372.2016.03.006.

孔令希, 邱峰, 王红梅, 等. 血浆置换联合双重血浆吸附治疗早、中、晚期肝衰竭的经济学评价[J]. 中华肝脏病杂志, 2020, 28(5): 434-440. https://doi.org/10.3760/cma.j.cn501113-20190122-00025https://doi.org/10.3760/cma.j.cn501113-20190122-00025.

KONG Lingxi, QIU Feng, WANG Hongmei, et al. Economic evaluation of plasma exchange combined with double plasma adsorption in the treatment of early, middle and late liver failure[J]. Chinese Journal of Liver Diseases, 2020, 28(5): 434-440. https://doi.org/10.3760/cma.j.cn501113-20190122-00025https://doi.org/10.3760/cma.j.cn501113-20190122-00025.

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure (2012 version)[J]. Chinese Journal of Hepatology, 2013, 21(3): 177-183.

Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J]. Hepatol Int, 2014, 8(4):453-471. https://doi.org/10.1007/s12072-014-9580-2https://doi.org/10.1007/s12072-014-9580-2.

Li J, Hu CH, Chen Y, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B[J]. BMC Infect Dis, 2021, 21(1): 567. https://doi.org/10.1186/s12879-021-06237-xhttps://doi.org/10.1186/s12879-021-06237-x.

Zhang YQ, Xu WX, Zhu X, et al. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: a prospective cohort study[J]. J Viral Hepat, 2021, 28(4): 592-600. https://doi.org/10.1111/jvh.13468https://doi.org/10.1111/jvh.13468.

Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4):672-681. https://doi.org/10.1016/j.jhep.2017.11.039https://doi.org/10.1016/j.jhep.2017.11.039.

石新星. HBV-ACLF及其合并急性肾损伤的预后相关因素研究[D]. 重庆: 第三军医大学, 2016.

SHI Xinxing. Prognostic risk factors of patients with hepatitis B virus-related acute-on-chronic liver failure and its combined acute renal injury[D]. Chongqing: Third Military Medical University, 2016.

康玮玮, 段丽萍, 徐曼曼, 等. 慢加急性肝衰竭与失代偿性肝硬化患者合并急性肾损伤的临床特点比较[J]. 中华肝脏病杂志, 2020, 28(5): 391-396. https://doi.org/10.3760/cma.j.cn501113- 20200417-00192https://doi.org/10.3760/cma.j.cn501113-20200417-00192.

KANG Weiwei, DUAN Liping, XU Manman, et al. Comparison of clinical features between patients with acute-on-chronic liver failure and decompensated liver cirrhosis combined with acute kidney injury[J]. Chinese Journal of Hepatology, 2020, 28(5): 391-396. https://doi.org/10.3760/cma.j.cn501113-20200417-00192https://doi.org/10.3760/cma.j.cn501113-20200417-00192.

浏览量

119

下载量

CSCD

工具集

关联资源

伊沙佐米治疗多发性骨髓瘤的临床研究

PI3K-Akt/mTOR/AMPK通路基因突变与鼻咽癌疗效及预后的关系

基于真实世界数据的冠状动脉药物涂层支架的临床应用效果

抗抑郁药的不良反应及其在心血管病患者中的应用

187例IB2和IIA2期宫颈癌新辅助化疗疗效及预后的影响因素